How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/treatment-of-moderate-to-severe-vasomotor-symptoms-associated-with-menopause.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Treatment of moderate to severe vasomotor symptoms associated with menopause — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treatment of moderate to severe vasomotor symptoms associated with menopause (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Treatment of moderate to severe vasomotor symptoms associated with menopause, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Duavee	conjugated-estrogens-bazedoxifene	Pfizer	Estrogen [EPC]	estrogen receptors α and β		2013-01-01
Duavee	Bazedoxifene Acetate	Pfizer Inc.	Estrogen agonist/antagonist combination	Estrogen receptors (ER) α and β

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 1 drug in Treatment of moderate to severe vasomotor symptoms associated with menopause
Pfizer Inc. · 1 drug in Treatment of moderate to severe vasomotor symptoms associated with menopause

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Treatment of moderate to severe vasomotor symptoms associated with menopause:

Cite this brief

Drug Landscape (2026). Treatment of moderate to severe vasomotor symptoms associated with menopause — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/treatment-of-moderate-to-severe-vasomotor-symptoms-associated-with-menopause. Accessed 2026-06-10.

Treatment of moderate to severe vasomotor symptoms associated with menopause full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing